MedTrace Logo

Safety And Efficacy Of Oral PF-4136309 In Patients With Chronic Hepatitis C Infection And Abnormal Liver Enzymes

NCT01226797 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2023-07-27

Study results available
· View outcomes & findings →

Summary

This study will evaluate the effect of PF-04136309 in patients with chronic hepatitic C virus infection and abnormal liver enzymes.

Conditions

  • Hepatitis C, Chronic

Interventions

DRUG

Placebo

Take 4 capsules twice daily 12 hours apart with water. Swallow whole.

DRUG

PF-04136309

Take 4 capsules twice daily 12 hours apart with water. Swallow whole.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-17
Primary Completion
2012-02-09
Completion
2012-02-09

Countries

  • Hong Kong
  • India
  • Singapore
  • South Korea
  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01226797 on ClinicalTrials.gov